Optomed and Toku Inc. enter a part­ner­ship to com­mer­cial­ize AI for car­dio­vas­cu­lar dis­ease risk

Optomed, a lead­ing man­u­fac­tur­er of hand­held fun­dus cam­eras and screen­ing soft­ware, has signed a glob­al part­ner­ship agree­ment with US-based arti­fi­cial intel­li­gence com­pa­ny, Toku Inc. The part­ner­ship aims to com­mer­cial­ize Toku’s CLAiR and BioAge with Optomed’s AI solu­tion plat­form glob­al­ly.

Toku spe­cial­izes in imag­ing tech­nol­o­gy and AI. The com­pa­ny recent­ly received the FDA’s Break­through Device des­ig­na­tion for its car­dio­vas­cu­lar risk detec­tion algo­rithm, CLAiR. Accord­ing to MDR, CLAiR has also achieved a CE des­ig­na­tion and a UKCA. Toku also has an AI soft­ware called BioAge that assess­es a person’s bio­log­i­cal age com­pared to their chrono­log­i­cal age, which is being com­mer­cial­ized in the Unit­ed States and glob­al­ly.

Optomed’s CEO, Juho Him­berg com­ments: “We are excit­ed to part­ner with Toku and see that this part­ner­ship aligns well with Optomed’s strat­e­gy to become a lead­ing provider of AI-enabled health­care solu­tions. Car­dio­vas­cu­lar dis­ease (CVD) is the lead­ing cause of death world­wide, with 49,000 deaths per day glob­al­ly. To be able to assess the risk for devel­op­ing CVD ear­ly on brings immense ben­e­fits to patients and the health­care sys­tem as a whole.”

Toku’s CEO, Ehsan Vagheri adds: “We are thrilled to enter this part­ner­ship with Optomed. Toku’s mis­sion is to make iden­ti­fy­ing dis­eases acces­si­ble for every­one, every­where, all the time We see great val­ue in mak­ing our tech­nol­o­gy avail­able with a hand­held fun­dus cam­era that does not require extra space at the clin­ic and allows mobile or at-home use.”

Con­tact per­son

Juho Him­berg

CEO, Optomed Plc

juho.himberg@optomed.com

Source: Optomed